Warten auf den Duke Report

Trillenium Medical Imaging (TMI) provides functional imaging systems through the use of infrared detection. This technology blends proprietary software with a highly durable and fully calibrated thermal detection device to record variances in body temperature.

Infrared thermal imaging is a non-invasive, imaging procedure involving the detection and recording of skin thermal patterns, providing visual and quantitative documentation. The interpretation of these temperatures and thermal patterns can play an important part in the development of a diagnosis. Because Infrared Imaging can display the variations in skin temperature patterns and these variations are known pathways of information, it can be invaluable as an integral part of the physical examination.

Such technology has been successfully tested and is currently in use to assist in diagnosis, treatment monitoring and case management of many health issues.  These include, but not limited to: vascular, neurological and muscular-skeletal disorders such as breast cancer, diabetes, and unresolved pain issues related to myofascial complaints, muscle injury or neurological dysfunction.
TMI is THE source for non-invasive Imaging devices for the treating professional who requires a physiological imaging test for diagnosis or case management.  

5. Oktober 2009 23:56

John Antonio,CEO of Wellstar International, Inc. (OTCBB:WLSI), today issued the following statement: As the CEO of Wellstar, I wanted to take the time to update all of our shareholders with the current status of the company, as well as the direction of where the company is headed. First and foremost are the Duke Study results. The study was designed to determine that long-wave infrared imaging can be used to identify skin temperature changes associated with underlying tissue changes. We wanted to determine if the use of Long Wave infrared imaging is as effective as the Braden Score in predicting nosocomial pressure ulcers. As the study has been completed for sometime, the results were put on hold for non-payment. In December 2008, Wellstar was able to make the payment that was due to Duke University. Since that time, we have been awaiting the final report. While the company was late making their payment, Wellstar lost their position of expedience with the final results. Since the payment has been made, we believe there have been great strides in the last few months in compiling the data and putting the data into a final report. Wellstar has received several of the drafts pertaining to the final report for publishing. Wellstar believes that the final results of the study will be published within the next 30 to 60 days.

With the publication of the study, Wellstar intends to raise enough capital to be able to run a minimum of two trials within the marketplace. We cannot provide any guarantee that we will be able to successfully raise capital, or if we do raise capital, that it will be on acceptable terms. These two trials will run simultaneously and allow for Wellstar to work out the installation and execution process of our system. It is anticipated that the trials will be for a period of between 90 and 120 days.

While the trials are being held, Wellstar will begin marketing its system. We will focus our efforts on hospitals, nursing homes and long term facilities. Another issue that I would like to address is the current volume of shares that are being traded. The high volumes of shares that are and have been selling are the result of our debt holder’s ability to convert into shares of common stock. Our promissory notes allow for the note holder to convert the outstanding principal and interest due to them into shares of common stock, which shares may be issued without a restrictive legend as the shares tack to the date of the issuance of the promissory notes under Rule 144. By the note holders converting to shares and selling into the marketplace, the company is reducing its debt. Until the company is cash flowing and able to meet it’s obligation to the note holders as well as its overhead, the conversions will continue. Wellstar will be making announcements to the public as they achieve any significant progress in the process of rollout and installation of their systems. Source: Wellstar International, Inc http://www.news-medical.net/news/20091005/...ial-pressure-ulcers.aspx

Wellstar International Announces Funding

HOLLAND, Ohio, Oct 14, 2009 (BUSINESS WIRE) -- Wellstar International, Inc. (OTCBB:WLSI), has announced that it has entered into a financing agreement with JMJ Financial to provide the Company with an expected $1.2 million dollars in operational funding over the eighteen months. Details of the financing were contained in the Company's Form 8-K filing with the Securities and Exchange Commission on October 9, 2009. The initial funding has been transferred to Wellstar and is expected to continue on a monthly basis. This funding will allow Wellstar to continue to operate in the near future and develop the completion of its Trillennium Medical Imaging System for rollout to the medical community. Although we have entered into a definitive agreements with respect to the financing with JMJ Financial, we cannot provide any guarantee that the funding outlined in the agreements will continue on a monthly basis or at all. Wellstar International, Inc. seeks to be the first-to-market in deep tissue injury and pressure ulcer detection using its proprietary infrared imaging system. Thermal Imaging is a low cost, noncontact, non-radioactive diagnostic screening procedure designed for clinical evaluation. In addition, thermal imaging provides an ability to track the progress of therapies being utilized in a low cost, non-invasive manner. Thermal Imaging can detect signs of pressure ulcers before they are visible with the naked eye through detection of temperature changes at the site which allows for treatment of the pressure ulcer before it erupts. The TMI system can be used to scan all new patients into hospitals and long-term care facilities prior admittance and begin treating existing wounds before they are visible. This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operation results.

SOURCE: Wellstar International, Inc.

 

Ich denke, da die Zahlungen durchgeführt wurden und der Duke Report am 05.Okt in Auftrag gegeben wurde, müsste hier bald etwas passieren. Nach Angaben des Unternehmen rechnete man mit 30-60 Tagen.
Gibt es Meinungen?  

Financal agreement with JMJ Financal

http://finance.yahoo.com/news/...onal-bw-1782672170.html?x=0&.v=1



Bezahlung Duke University und Erwartung des Duke Report

http://www.news-medical.net/news/20091005/...ial-pressure-ulcers.aspx  

Wenn ich mir die Bilanzen ansehe, sieht es nicht sehr gut aus für das Unternehmen. Hier ein Link über die Quartalszahlen 2006/07 - 2008/07, für das jetzige Quartal wurde eine Aufschiebung gestern eingereicht.

http://ih.advfn.com/...agelist=Quote&mode=&symbol=USBB%3AWLSI

hier die Aufschiebung:

http://ih.advfn.com/...9290&article=40759579&symbol=NB%5EWLSI

Ich denke man hofft auf ein positives Ergebnis des Duke Reports, welcher angeblich schon überfällig ist und verschiebt dadurch die Quartalszahlen.
Wer weiß was passiert, wenn der Bericht gut ausfällt und die Geräte / Software ausgeliefert wird. Die FDA hat es ja schon freigegeben, soweit ich es verstanden habe.

The TMI technology and software is approved by the FDA as an Adjunctive Diagnostic screening procedure for early breast cancer detection, differential diagnosis of pain dysfunctions, (such as Reflex Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and Neurological disorders), the early detection of pressure ulcers, deep tissue injuries, and bed sores, as well as orthopedic applications. The Company’s imaging research concurrently looks to initiate consideration of thermography as a viable tool and a medical standard for predicting and preventing pressure ulcers in the medical community.  

die Thermografie mit Software wurde zugelassen.

Sie warten aber auf den Quartalsbericht, der wurde gestern verschoben. Sie wollen ihn noch vor oder am 15ten Kalendertag (spätestens 29.12.) vorlegen. Wenn dieser vorliegt und positiv ausfällt, dann kann das Ding abgehen. Heute über 280Mill. gehandelt, naja sind auch jede Menge im Umlauf. Ich hab mal Spielgeld eingesetzt und 4Mill. zu .0001$ geordert. Hört sich enorm an, sind aber nur 400$ (272€). :)

nur ist meine Order zu .0001 nicht durchgegangen. Musste dann .0002$ nehmen.

Wenn die Thermografie und Software bereits zugelassen wurden, heißt es ja im Umkehrschluss, dass der Report im Prinzip nicht schlecht ausfallen dürfte.
Man erhofft sich also mit der Veröffentlichung des Berichts nur Kapital für die letzten Installationen und Vorbereitungen zu erhalten und gleichzeitig die Vermarktung anzutreiben.
Hoffen wir mal auf den Quartalsbericht  

die Verschiebung der Finanzberichte ist bei denen wohl an der Tagesordnung

http://www.pinksheets.com/pink/quote/...mp;symbol=WLSI&tabValue=1  

..falls es nichts werden sollte, ist auch nicht viel kaputt gegangen.:) Ich lass die Aktien mal in der Ecke liegen und harre der Dinge, die da kommen mögen.

Axo, der Chef wird als unqualifiziert eingestuft.:(

Die Shares sollen gesplittet werden im Verhältnis 100:1.
140 Mio. bleiben in Eigenbesitz
200 Mio. Free Flow

Deswegen ist zur Zeit nur Abverkauf, Split gleich Verlust?



- Current report filing (8-K)
Date : 12/18/2009 @ 6:02AM
Source : Edgar (US Regulatory)
Stock : (WLSI)
Quote :  0.0001  0.0 (0.00%) @ 2:05AM


- Current report filing (8-K)





--------------------------------------------------

--------------------------------------------------

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934


Date of Report (Date of earliest reported):  December 15, 2009


WELLSTAR INTERNATIONAL, INC.
(Exact name of registrant as specified in charter)


Nevada  333-130295  20-1834908  
(State  or  Other  Jurisdiction of Incorporation or Organization)  (Commission File Number)  (IRS Employer Identification No.)  



6911 Pilliod Road
Holland, Ohio 43528
(Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (419) 865-0069




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

--------------------------------------------------

--------------------------------------------------


--------------------------------------------------



Item 5.03  Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.  



On December 15, 2009, Wellstar International, Inc. (the “Company”) filed a Certificate of Change with the State of Nevada to reverse split the outstanding and authorized common stock on a basis of one for 100 shares of common stock resulting in a decrease in the number of authorized issued and outstanding shares at the ratio of 100 for one.  No fractional shares shall be issued. In lieu of issuing fractional shares, the Company will issue to any shareholder who otherwise would have been entitled to receive a fractional share as a result of the reverse split an additional full share of its common stock.  The above transactions were approved by the Board of Directors of the Company.  The effective date of the reverse split is January 15, 2010.  As a result of the reverse split, the Company will have approximately 140,000,000 shares issued and outstanding and 200,000,000 shares of common stock authorized.


The foregoing information is a summary of each of the agreements involved in the transactions described above, is not complete, and is qualified in its entirety by reference to the full text of those agreements, each of which is attached an exhibit to this Current Report on Form 8-K.  Readers should review those agreements for a complete understanding of the terms and conditions associated with this transaction.


Item 9.01 Financial Statements and Exhibits


(c) Exhibits.
 
Exhibit
Number  Description  
------------  --------------------------------------------------  
3.1  Certificate of Change to the Certificate of Incorporation  

 
 

 
SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
  WELLSTAR INTERNATIONAL, INC.    
       
           
Date: December 16, 2009  By:  /s/ John Antonio    
     Name: John Antonio    
     Title: CEO

Quartalsbericht wurde eingereicht

http://www.microcapmarkets.com/...35&market=OTCBB&ticker=WLSI  

So, der R/S ist durch. Preis von $ 0,01 ist bei mir im Depot schon eingepflegt. Anzahl der Aktien wird noch nicht angezeigt.

Jetzt könnte hier mal was passieren. Ich weiß nicht, was mit denen los ist.
Vllt warten die mit der Veröffentlichung des Duke Repots bis nach dem RS?  

- Amended Current report filing (8-K/A)
Date : 01/19/2010 @ 11:07AM
Source : Edgar (US Regulatory)
Stock : (WLSID)
Quote :  0.0033  -0.0002 (-5.71%) @ 8:04AM


- Amended Current report filing (8-K/A)




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549


FORM 8-K/A


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934


Date of Report (Date of earliest reported):  December 15, 2009


WELLSTAR INTERNATIONAL, INC.
(Exact name of registrant as specified in charter)


Nevada  333-130295  20-1834908  
(State  or  Other  Jurisdiction of
Incorporation or Organization)  (Commission File Number)  (IRS Employer Identification No.)  



6911 Pilliod Road
Holland, Ohio 43528
(Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (419) 865-0069




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
     
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
     
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
     
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

 
 
 

--------------------------------------------------

 
 
 
 
Item 5.03            Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.


On December 15, 2009, Wellstar International, Inc. (the “Company”) filed a Certificate of Change with the State of Nevada to reverse split the outstanding and authorized common stock on a basis of one for 100 shares of common stock resulting in a decrease in the number of authorized issued and outstanding shares at the ratio of 100 for one.  No fractional shares shall be issued. In lieu of issuing fractional shares, the Company will issue to any shareholder who otherwise would have been entitled to receive a fractional share as a result of the reverse split an additional full share of its common stock.  The above transactions were approved by the Board of Directors of the Company.  The effective date of the reverse split was January 15, 2010.  As a result of the reverse split, the Company will have approximately 200,000,000 shares issued and outstanding and 200,000,000 shares of common stock authorized.


On January 14, 2010, the Company was informed by FINRA that it approved the reverse split for the Company which took effect at the open of business on January 15, 2010.  FINRA advised the Company that a “D” will be placed on the trading symbol as a 5 th character.  The new Company symbol as of January 15, 2010 will be WLSID.  The “D” will remain as part of our symbol for 20 business days.


The foregoing information is a summary of each of the agreements involved in the transactions described above, is not complete, and is qualified in its entirety by reference to the full text of those agreements, each of which is attached an exhibit to this Current Report on Form 8-K.  Readers should review those agreements for a complete understanding of the terms and conditions associated with this transaction.


Item 9.01 Financial Statements and Exhibits


(c) Exhibits.


Exhibit    
Number  Description                                                                                                            
     
3.1  Certificate of Change to the Certificate of Incorporation (1)  



(1)  Incorporated by reference to the Form 8-K Current Report filed by the Securities and Exchange Commission on December 18, 2009


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


WELLSTAR INTERNATIONAL, INC.




Date: January 19, 2010  By:  /s/ John Antonio  
     Name: John Antonio  
     Title: CEO  

Wellstar International, Inc. Announces the Submission of the Results of the Study for Publication of the Duke University Study
Date : 01/20/2010 @ 7:30AM
Source : Business Wire
Stock : Wellstar International Inc. (WLSID)
Quote :  0.0033  -0.0002 (-5.71%) @ 8:04AM


Wellstar International, Inc. Announces the Submission of the Results of the Study for Publication of the Duke University Study




Wellstar International Inc. (OTCBB:WLSI) has announced the manuscript of the successful results from the completed study at Duke University has been submitted for publishing to the ADVANCES IN SKIN AND WOUND CARE PUBLICATION JOURNAL on Monday, January 18, 2010. Trillennium Medical Imaging (TMI), a wholly owned subsidiary of Wellstar International Inc., is satisfied with the results of this study, of which the details will be released upon publication, which unfortunately due to protocol will not be for several months. After their acceptance of the manuscript we will comment further

The study was designed to determine that long-wave infrared imaging can be used to identify skin temperature changes associated with underlying tissue changes. We wanted to determine if the use of Long Wave infrared imaging will be more effective than the Braden Score in predicting nosocomial pressure ulcers. The Braden Scale is the current Gold Standard used within the industry for determining the possibility of an existing pressure ulcer, and our goal is to replace the Braden Scale with the TMI System as the Gold Standard within the industry

With the results being submitted for publication of the study, our next stage in development will focus on running Beta Tests within the marketplace subject to obtaining the needed capital. We cannot provide any guarantee that we will be able to successfully raise capital, or if we do raise capital, that it will be on acceptable terms. These two Beta Tests will run simultaneously and allow for Wellstar to work out the installation and execution process of our system. It is anticipated that the Beta Test will be for a period of between 90 and 120 days after commencement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operation results

es eigentlich losgehen, aber der Kurs sträubt sich noch. SK $0,0033

Ich glaube die Altaktionäre sind noch negativ gestimmt. Abwarten und Tee trinken.;)

ja schon mal gute Nachrichten.

Die Beta-Test-Phase dauert ja jetzt etwas und hoffe, dass das Geld bis dahin reicht. Man bemüht sich zumindest gleichzeitig die Vermarktung anzutreiben.
Bei den Ergebnissen müsste ja im Notfall noch ein Investor zu finden sein  

http://finance.yahoo.com/q/is?s=wlsid.ob  

Seit dem R/S wird der aktuelle Kurs nicht mehr hier angezeigt, sondern unter:

WELLSTAR INTL NEW  

WKN A0YJQ4

ISIN US9499022096

Kann man dieses Forum irgendwie unter der neuen WKN einpflegen?  

Welchen Ziel sollte eigentlich mit dem R/S verfolgt werden? (Klar Begrenzung der Aktienanzahl)

Das der Aktienwert fällt bei nicht wirklich guten News war doch aber eigentlich klar. Aber dass man bei einem schon sehr geringen Firmenwert (weniger ging ja nicht mehr außer Delisting) innerhalb einer Woche noch mal knapp 70% verliert macht diese ganze Aktion noch unverständlicher.  

waren doch gut. Der Report ist doch gut ausgefallen und zugelassen ist das Ding auch schon.
Ich denke, da die nächsten drei Monate an dem Beta-Test gearbeitet wird passiert hier nicht viel.

Man muss jetzt die Vermarktung vorantreiben und bis dahin, hoffe ich, reicht die Kohle. Vermillion hatte auch nur einen sehr geringen Firmenwert.

Ich denke die R/S war nur um die Aktienanzahl zu mindern und den Kurs interessanter zu machen.

Warten wir mal ab.  

26-Jan-2010

Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fin


Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Increase to Authorized

On January 22, 2010, Wellstar International, Inc. (the "Company") amended its certificate of incorporation to increase its authorized shares of common stock from 200,000,000 to 5,000,000,000 (the "Increase Amendment"). The Increase Amendment was approved by the board of directors as well as the shareholders holding a majority of the issued and outstanding shares of common stock pursuant to a written consent dated January 21, 2010.

Series B Preferred Stock

On January 19, 2010, the Company entered into a conversion agreement with John Antonio ("Antonio") and Kenneth McCoppen ("McCoppen"), both executive officers and directors of the Company, pursuant to which the Company agreed to convert $50,000 in outstanding wages owed to each McCoppen and Antonio into a total of 50,000 shares of Series B Preferred Stock.

The above transactions were approved by the Board of Directors of the Company. The Series B Preferred Stock does not pay dividends but each holder of Series B Preferred Stock shall be entitled to 100 votes for each share of common stock that the Series B Preferred Stock shall be convertible into. The Series B Preferred Stock has a conversion price of $0.001 (the "Conversion Price") and a stated value of $1.00 (the "Stated Value"). Each share of Series B Preferred Stock is convertible, at the option of the holder, into such number of shares of common stock of the Company as determined by dividing the Stated Value by the Conversion Price. The Series B Preferred Stock has no liquidation preference.

The issuance of the Series B Preferred Stock was made in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933 and Rule 506 promulgated under Regulation D thereunder. The holders of Series B Preferred Stock are accredited investors as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933.

The foregoing information is a summary of each of the agreements involved in the transactions described above, is not complete, and is qualified in its entirety by reference to the full text of those agreements, each of which is attached an exhibit to this Current Report on Form 8-K. Readers should review those agreements for a complete understanding of the terms and conditions associated with this transaction.

-REMAINDER OF PAGE INTENTIONALLY LEFT BLANK-

Tolle Aktion!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!  

Kann es sein, dass man weiteres Kapital für die Tests braucht?

...Man wartet also mit der Veröffentlichung des Duke Reportes bis zum Resplitt, in der Hoffnung einen eventuell fallenden Kurs aufhalten zu können.
Das ist ja mal in die Buxe gegangen...also braucht man jetzt neues Kapital um die Tests weiter zu führen und um die 3-4 Monate zu überbrücken. Oder sehe ich das falsch?
Solange man hier an der Insolvenz vorbei schrammt, solls mir egal sein.  

Sieht für mich wie eine Geldbeschaffungsmaßnahme aus. Erst RS und dann Aktienanzahl wieder erhöhen. Das nennt man dann wohl Verwässerung des Kurses.  

wird wohl der erfolgreiche Beta-Test und die Vermarktung sein :-) ....oder die totale Pleite